TABLE 1

Kinase rearrangement and therapeutic targets in Ph-like ALL. The TKIs shown are known or predicted to be active against rearrangements involving the listed kinase in experimental models but, with the exception of imatinib/dasatinib in EBF1-PDGFRB ALL, have not been shown to be effective in ALL [data from Roberts et al. (2014) and adapted from Mullighan (2014)].

KinaseTKINo. of PartnersNo. of Cases5′ Genes
ABL1Dasatinib614ETV6, NUP214, RCSD1, RANBP2, SNX2, ZMIZ1
ABL2Dasatinib37PAG1, RCSD1, ZC3HAV1
CSF1RDasatinib14SSBP2
PDGFRBDasatinib411EBF1, SSBP2, TNIP1, ZEB2
CRLF2JAK2 Inhibitor230IGH, P2RY8
JAK2JAK2 Inhibitor1019ATF7IP, BCR, EBF1, ETV6, PAX5, PPFIBP1, SSBP2, STRN3, TERF2, TPR
EPORJAK2 Inhibitor29IGH, IGK
DGKHUnknown11ZFAND3
IL2RBJAK1/3 inhibitor11MYH9
NTRK3Crizotinib, LOXO-10111ETV6
PTK2BFAK inhibitor21KDM6A
TSLPJAK2 Inhibitor11IQGAP2
TYK2TYK2 inhibitor11MYB